Ray Dorsey, E. et al. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 17, 939–953 (2018).

Article  Google Scholar 

Dauer, W. & Przedborski, S. Parkinson’s disease: mechanisms and models. Neuron 39, 889–909 (2003).

CAS  PubMed  Article  PubMed Central  Google Scholar 

Kalia, L. V. & Lang, A. E. Parkinson’s disease. Lancet 386, 896–912 (2015).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Obeso, J. A. Past, present, and future of Parkinson’s disease. Mov. Disord. 32, 1263–1263 (2017).

Article  Google Scholar 

Marsili, L., Rizzo, G. & Colosimo, C. Diagnostic criteria for Parkinson’s disease: from James Parkinson to the concept of prodromal disease. Front. Neurol. 9, 1–10 (2018).

Article  Google Scholar 

Goetz, C. G. et al. Movement disorder society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov. Disord. 22, 41–47 (2007).

MathSciNet  PubMed  Article  Google Scholar 

Gelb, D. J., Oliver, E. & Gilman, S. Diagnostic criteria for Parkinson disease. Arch. Neurol. 56, 33–39 (1999).

CAS  PubMed  Article  PubMed Central  Google Scholar 

Jankovic, J. Parkinson’s disease clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry 79, 386–376 (2008).

Article  Google Scholar 

Hawkes, C. H. The prodromal phase of sporadic Parkinson’s disease: Does it exist and if so how long is it? Mov. Disord. 23, 1799–1807 (2008).

PubMed  Article  Google Scholar 

Hawkes, C. H., Del Tredici, K. & Braak, H. A timeline for Parkinson’s disease. Park. Relat. Disord. 16, 79–84 (2010).

Article  Google Scholar 

Ravn, A.-H., Thyssen, J. P. & Egeberg, A. Skin disorders in Parkinson’s disease: potential biomarkers and risk factors. Clin. Cosmet. Investig. Dermatol. 10, 87–92 (2017).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Mastrolonardo, M., Diaferio, A. & Logroscino, G. Seborrheic dermatitis, increased sebum excretion, and Parkinson’s disease: a survey of (im) possible links. Med. Hypotheses 60, 907–911 (2003).

CAS  PubMed  Article  PubMed Central  Google Scholar 

Stewart, M. E. & Downing, D. T. Chemistry and Function of Mammalian Sebaceous Lipids. Advances in Lipid Research vol. 24 (Academic Press, 1991).

Lovászi, M., Szegedi, A., Zouboulis, C. C. & Törőcsik, D. Sebaceous-immunobiology is orchestrated by sebum lipids. Dermatoendocrinology 9, 1–10 (2018).

Google Scholar 

Picardo, M. et al. Sebaceous gland lipids. Dermatoendocrinology 1, 68–71 (2009).

CAS  Article  Google Scholar 

Trivedi, D. K. et al. Discovery of volatile biomarkers of Parkinson’s disease from sebum. ACS Cent. Sci. 5, 599–606 (2019).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Dunn, W. B., Broadhurst, D. I., Atherton, H. J., Goodacre, R. & Griffin, J. L. Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem. Soc. Rev. 40, 387–426 (2011).

CAS  PubMed  Article  PubMed Central  Google Scholar 

Dunn, W. B. et al. Mass appeal: metabolite identification in mass spectrometry-focused untargeted metabolomics. Metabolomics 9, 44–66 (2013).

CAS  Article  Google Scholar 

Shao, Y. & Le, W. Recent advances and perspectives of metabolomics-based investigations in Parkinson’s disease. Mol. Neurodegener. 14, 1–12 (2019).

CAS  Article  Google Scholar 

Cova, I. & Priori, A. Diagnostic biomarkers for Parkinson’s disease at a glance: where are we? J. Neural Transm. 125, 1417–1432 (2018).

CAS  PubMed  Article  PubMed Central  Google Scholar 

Havelund, J. F., Heegaard, N. H. H., Færgeman, N. J. K. & Gramsbergen, J. B. Biomarker research in Parkinson’s disease using metabolite profiling. Metabolites 7, 42 (2017).

Goldstein, D. S., Holmes, C., Lopez, G. J., Wu, T. & Sharabi, Y. Cerebrospinal fluid biomarkers of central dopamine deficiency predict Parkinson’s disease. Park. Relat. Disord. 50, 108–112 (2018).

Article  Google Scholar 

Mattsson, N. CSF biomarkers in neurodegenerative diseases. Clin. Chem. Lab. Med. 49, 345–352 (2011).

CAS  PubMed  Article  PubMed Central  Google Scholar 

Engelborghs, S., Marescau, B. & De Deyn, P. P. Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson’s disease. Neurochem. Res. 28, 1145–1150 (2003).

CAS  PubMed  Article  PubMed Central  Google Scholar 

Hong, Z. et al. DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain 133, 713–726 (2010).

PubMed  PubMed Central  Article  Google Scholar 

D’Andrea, G. et al. Different circulating trace amine profiles in de novo and treated Parkinson’s disease patients. Sci. Rep. 9, 1–11 (2019).

Article  CAS  Google Scholar 

LeWitt, P. A. et al. Metabolomic biomarkers as strong correlates of Parkinson disease progression. Neurology 88, 862–869 (2017).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Saiki, S. et al. Decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for Parkinson’s disease. Sci. Rep. 7, 1–15 (2017).

ADS  Article  CAS  Google Scholar 

Cipriani, S., Chen, X. & Schwarzschild, M. A. Urate: a novel biomarker of Parkinsons disease risk, diagnosis and prognosis. Biomark. Med. 4, 701–712 (2010).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Moisan, F. et al. Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis. J. Neurol. Neurosurg. Psychiatry 87, 952–957 (2016).

PubMed  Article  PubMed Central  Google Scholar 

Chawla, N. V., Bowyer, K. W., Hall, L. O. & Kegelmeyer, P. W. SMOTE: synthetic minority over-sampling technique. J. Artif. Intell. Res. 16, 321–357 (2002).

MATH  Article  Google Scholar 

Sumner, L. W. et al. Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Inititative (MSI). Metabolomics 3, 211–221 (2007).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Liebisch, G. et al. Shorthand notation for lipid structures derived from mass spectrometry. J. Lipid Res. 54, 1523–1530 (2013).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Li, S. et al. Predicting network activity from high throughput metabolomics. PLoS Comput. Biol. 9, e1003123 (2013).

Longo, N., Frigeni, M., Pasquali, M., Biophys, B. & Author, A. Carnitine transport and fatty acid oxidation. Biochim. Biophys. Acta 1863, 2422–2435 (2016).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Rattray, N. J. W. et al. Metabolic dysregulation in vitamin E and carnitine shuttle energy mechanisms associate with human frailty. Nat. Commun. 10, 1–12 (2019).

CAS  Article  Google Scholar 

Alecu, I. & Bennett, S. A. L. Dysregulated lipid metabolism and its role in α-synucleinopathy in Parkinson’s disease. Front. Neurosci. 13, 1–22 (2019).

Article  Google Scholar 

Lin, G., Wang, L., Marcogliese, P. C. & Bellen, H. J. Sphingolipids in the pathogenesis of Parkinson’s disease and Parkinsonism. Trends Endocrinol. Metab. 30, 106–117 (2019).

CAS  Article  Google Scholar 

Donadio, V. et al. Skin nerve alpha-synuclein deposits: a biomarker for idiopathic Parkinson disease. Neurology 82, 1362–1369 (2014).

CAS  PubMed  Article  PubMed Central  Google Scholar 

Xicoy, H., Wieringa, B. & Martens, G. J. M. The role of lipids in Parkinson’s disease. Cells 8, 27 (2019).

CAS  PubMed Central  Article  Google Scholar 

Indellicato, R. & Trinchera, M. The link between Gaucher disease and Parkinson’s disease sheds light on old and novel disorders of sphingolipid metabolism. Int. J. Mol. Sci. 20, 3304 (2019).

CAS  PubMed Central  Article  Google Scholar 

Isacson, O., Brekk, O. R. & Hallett, P. J. Novel results and concepts emerging from lipid cell biology relevant to degenerative brain aging and disease. Front. Neurol. 10, 1–8 (2019).

Article  Google Scholar 

Hallett, P. J., Engelender, S. & Isacson, O. Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson’s disease. J. Neuroinflamm. 16, 1–15 (2019).

CAS  Article  Google Scholar 

Hoyo, P. et al. Oxidative stress in skin fibroblasts cultures from patients with Parkinson’ s disease. BMC Neurol. 10, 1–7 (2010).

Article  Google Scholar 

Mortiboys, H. et al. Mitochondrial function and morphology are impaired in parkin mutant fibroblasts. Ann. Neurol. 64, 555–565 (2008).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Kurz, J., Parnham, M. J., Geisslinger, G. & Schiffmann, S. Ceramides as novel disease biomarkers. Trends Mol. Med. 25, 20–32 (2019).

CAS  PubMed  Article  Google Scholar 

Plotegher, N., Bubacco, L., Greggio, E. & Civiero, L. Ceramides in Parkinson’s disease: from recent evidence to new hypotheses. Front. Neurosci. 13, 1–7 (2019).

Article  Google Scholar 

Mielke, M. M. et al. Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson’s disease and associated with cognitive impairment: a pilot study. PLoS ONE 8, 1–6 (2013).

Article  CAS  Google Scholar 

Gulati, S., Liu, Y., Munkacsi, A. B., Wilcox, L. & Sturley, S. L. Sterols and sphingolipids: dynamic duo or partners in crime? Prog. Lipid Res. 49, 353–365 (2010).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Liang, J. J. & Rasmusson, A. M. Overview of the molecular steps in steroidogenesis of the GABAergic neurosteroids allopregnanolone and pregnanolone. Chronic Stress 2, 247054701881855 (2018).

Article  Google Scholar 

Verschuur, C. V. M. et al. Randomized delayed-start trial of levodopa in Parkinson’s disease. N. Engl. J. Med. 380, 315–324 (2019).

CAS  PubMed  Article  PubMed Central  Google Scholar 

Dunn, W. B. et al. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat. Protoc. 6, 1060–1083 (2011).

CAS  PubMed  PubMed Central  Article  Google Scholar